LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply
AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.
-
Filed today
-
Companies tracked
NSE & BSE
Listed on
👋Welcome back, there - you're tracking 0 companies
🔔Sign in free to track companies and get alerts the moment they file
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors
Latest Filings -
📋 Filing Types Available on ForgeUp Filings
Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
The company has announced a Board meeting on May 5 to approve its year-end profit results and decide whether to pay dividends to shareholders.
🤖 AI Summary
Board meeting scheduled May 5, 2026, to approve Q4 and FY26 audited results
Dividend recommendation will be considered at the same meeting
Meeting to be held at company registered office
Filing issued under Reg 29(1) LODR — interim intimation, not financial disclosure
🏢 How This Affects the Company
💰
Financial Impact
Approval of audited FY26 results will confirm full-year financial performance. Dividend recommendation, if approved, will reduce retained cash available for operations or reinvestment.
👥 What This Means For Shareholders
✅
Action Required
No action required before May 5. After results are announced, note the dividend record date if declared.
👤
Who Is Affected
All shareholders of record hold voting rights, but dividend eligibility depends on holding status on record date after Board approval.
🔍
Management Signal
Routine Board governance process confirms company is progressing towards formal results disclosure as a listed entity.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
Dividend declaration and record date — check if announced in post-Board filing
Q1 FY27 guidance or management commentary on FY26 performance trends
LOW RISKRoutine Board intimation. No material events, transactions, or anomalies disclosed. Standard corporate governance process.
💡 Investor Takeaway
Board will formally approve FY26 audited results and consider dividend on May 5, 2026. Actual financial metrics and dividend amount will be disclosed in subsequent Reg 41 announcement. No forward guidance or interim figures in this intimation.
📅 Company Track Record
No previous BSE filings on record for Jenburkt Pharmaceuticals. Company incorporation and IPO listing date not disclosed in available filings. First financial results disclosure expected May 5, 2026.
Based on publicly available historical data. For context only.
All BSE filings we have analysed for Jenburkt Pharmaceuticals Ltd.
You've read one filing
There are 32,000 more, and one of them is about a company you own
Follow a company and we'll email you the moment it files
again - explained, not just forwarded. Free.
Follow companies and get filings by email
Save any filing to read later
Two full AI analyses every month, free
No card needed. Sign in with Google in two taps.
⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔖
Save filings you care about
Sign in free to save any filing and get notified when the same company files again.
🔖
Save This Filing
Sign in with Google to save this filing and get notified when this company files again. Free, takes 5 seconds.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.